Quarterly report pursuant to Section 13 or 15(d)

Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)

v3.22.2.2
Schedule of Net Assets Acquired to be Allocated to Goodwill (Details) - USD ($)
Apr. 16, 2021
Jun. 30, 2022
Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]      
Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill   $ 10,498,539 $ 10,498,539
Akers Biosciences, Inc [Member]      
Restructuring Cost and Reserve [Line Items]      
Total Consideration $ 42,477,346    
Cash and Cash Equivalents 1,380,852    
Marketable Securities 29,480,524    
Other Receivables 3,026,137    
Prepaid Expenses 192,314    
Investment in Oravax, Inc. 1,500,000    
Trade and Other Payables (3,601,020)    
Net Tangible Assets Acquired 31,978,807    
Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill $ 10,498,539